| Year |
Citation |
Score |
| 2023 |
Burikhanov R, Ganguly S, Ellingson S, Sviripa VM, Araujo N, Li S, Venkatraman P, Rao M, Choughule A, Brainson CF, Zhan CG, Spielmann HP, Watt DS, Govindan R, Rangnekar VM. Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition. American Journal of Cancer Research. 13: 976-991. PMID 37034206 |
0.422 |
|
| 2022 |
Ding N, Jiang H, Thapa P, Hao Y, Alshahrani A, Allison D, Izumi T, Rangnekar VM, Liu X, Wei Q. Peroxiredoxin IV plays a critical role in cancer cell growth and radioresistance through the activation of the Akt/GSK3 signaling pathways. The Journal of Biological Chemistry. 102123. PMID 35697073 DOI: 10.1016/j.jbc.2022.102123 |
0.441 |
|
| 2021 |
Mello-Andrade F, Guedes APM, Pires WC, Velozo-Sá VS, Delmond KA, Mendes D, Molina MS, Matuda L, de Sousa MAM, Melo-Reis P, Gomes CC, Castro CH, Almeida MAP, Menck CFM, Batista AA, ... ... Rangnekar VM, et al. Ru(II)/amino acid complexes inhibit the progression of breast cancer cells through multiple mechanism-induced apoptosis. Journal of Inorganic Biochemistry. 226: 111625. PMID 34655962 DOI: 10.1016/j.jinorgbio.2021.111625 |
0.344 |
|
| 2020 |
Thayyullathil F, Cheratta AR, Pallichankandy S, Subburayan K, Tariq S, Rangnekar VM, Galadari S. Par-4 regulates autophagic cell death in human cancer cells via upregulating p53 and BNIP3. Biochimica Et Biophysica Acta. Molecular Cell Research. 118692. PMID 32135176 DOI: 10.1016/J.Bbamcr.2020.118692 |
0.533 |
|
| 2019 |
Kim K, Araujo P, Hebbar N, Zhou Z, Zheng X, Zheng F, Rangnekar VM, Zhan CG. Development of a novel prostate apoptosis response-4 (Par-4) protein entity with an extended duration of action for therapeutic treatment of cancer. Protein Engineering, Design & Selection : Peds. PMID 31711233 DOI: 10.1093/Protein/Gzz034 |
0.497 |
|
| 2019 |
Greene JT, Mani R, Ramaswamy R, Frissora F, Yano M, Zapolnik K, Harrington B, Wasmuth R, Tran M, Mo X, McKenna M, Rangnekar VM, Byrd JC, Bondada S, Muthusamy N. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling. Blood Advances. 3: 1255-1266. PMID 30987970 DOI: 10.1182/Bloodadvances.2018025973 |
0.423 |
|
| 2018 |
Wang P, Burikhanov R, Jayswal R, Weiss HL, Arnold SM, Villano JL, Rangnekar VM. Neoadjuvant administration of hydroxychloroquine in a phase 1 clinical trial induced plasma Par-4 levels and apoptosis in diverse tumors. Genes & Cancer. 9: 190-197. PMID 30603055 DOI: 10.18632/Genesandcancer.181 |
0.349 |
|
| 2018 |
He C, Plattner R, Rangnekar V, Zhou B, Liu C, Stewart RL, Huang B, Wang C, Tucker TC. Potential protein markers for breast cancer recurrence: a retrospective cohort study. Cancer Causes & Control : Ccc. PMID 30488343 DOI: 10.1007/S10552-018-1099-8 |
0.344 |
|
| 2018 |
Araujo N, Hebbar N, Rangnekar VM. GRP78 Is a Targetable Receptor on Cancer and Stromal Cells. Ebiomedicine. PMID 29997052 DOI: 10.1016/J.Ebiom.2018.06.030 |
0.371 |
|
| 2018 |
McKenna MK, Noothi SK, Alhakeem SS, Oben KZ, Greene JT, Mani R, Perry KL, Collard JP, Rivas JR, Hildebrandt G, Fleischman R, Durbin EB, Byrd JC, Wang C, Muthusamy N, ... Rangnekar VM, et al. Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia. Blood. PMID 29695515 DOI: 10.1182/Blood-2017-10-813931 |
0.55 |
|
| 2018 |
Shukla N, Zhao Y, Rangnekar V. PAWR (PRKC apoptosis WT1 regulator protein; Prostate apoptosis response-4, Par-4) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/66070 |
0.474 |
|
| 2018 |
Wang P, Weiss H, Arnold SM, Villano JL, Leggas M, Rangnekar V. A pilot, phase I clinical trial to determine the biological effects of hydroxychloroquine (HCQ) on par-4 levels in patients with surgically removable solid tumors. Journal of Clinical Oncology. 36: e14555-e14555. DOI: 10.1200/Jco.2018.36.15_Suppl.E14555 |
0.496 |
|
| 2017 |
Hebbar N, Burikhanov R, Shukla N, Qiu S, Zhao Y, Elenitoba-Johnson KSJ, Rangnekar VM. A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in Tumors. Cancer Research. PMID 28625975 DOI: 10.1158/0008-5472.Can-16-1970 |
0.455 |
|
| 2017 |
Oben KZ, Gachuki BW, Alhakeem SS, McKenna MK, Liang Y, St Clair DK, Rangnekar VM, Bondada S. Radiation Induced Apoptosis of Murine Bone Marrow Cells Is Independent of Early Growth Response 1 (EGR1). Plos One. 12: e0169767. PMID 28081176 DOI: 10.1371/Journal.Pone.0169767 |
0.447 |
|
| 2017 |
Burikhanov R, Hebbar N, Noothi SK, Shukla N, Sledziona J, Araujo N, Kudrimoti M, Wang QJ, Watt DS, Welch DR, Maranchie J, Harada A, Rangnekar VM. Chloroquine-Inducible Par-4 Secretion Is Essential for Tumor Cell Apoptosis and Inhibition of Metastasis. Cell Reports. 18: 508-519. PMID 28076793 DOI: 10.1016/J.Celrep.2016.12.051 |
0.519 |
|
| 2016 |
Singh AK, Chauhan SS, Singh SK, Verma V, Singh A, Arya RK, Maheshwari S, Akhtar MS, Sarkar J, Rangnekar VM, Chauhan PM, Datta D. Dual Targeting of MDM2 with a Novel Small Molecule Inhibitor Overcomes TRAIL Resistance in Cancer. Carcinogenesis. PMID 27543608 DOI: 10.1093/Carcin/Bgw088 |
0.461 |
|
| 2015 |
Sviripa VM, Burikhanov R, Obiero JM, Yuan Y, Nickell JR, Dwoskin LP, Zhan CG, Liu C, Tsodikov OV, Rangnekar VM, Watt DS. Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin. Organic & Biomolecular Chemistry. PMID 26548370 DOI: 10.1039/C5Ob01980J |
0.48 |
|
| 2015 |
Sarkar S, Jain S, Rai V, Sahoo DK, Raha S, Suklabaidya S, Senapati S, Rangnekar VM, Maiti IB, Dey N. Plant-derived SAC domain of PAR-4 (Prostate Apoptosis Response 4) exhibits growth inhibitory effects in prostate cancer cells. Frontiers in Plant Science. 6: 822. PMID 26500666 DOI: 10.3389/Fpls.2015.00822 |
0.508 |
|
| 2015 |
Frasinyuk MS, Bondarenko SP, Sviripa VM, Burikhanov R, Rangnekar VM, Liu C, Watt DS. Development of 6H-Chromeno[3,4-c]pyrido[3',2':4,5]thieno[2,3-e]pyridazin-6-ones as Par-4 Secretagogues. Tetrahedron Letters. 56: 3382-3384. PMID 26236052 DOI: 10.1016/J.Tetlet.2015.01.028 |
0.423 |
|
| 2015 |
McKenna MK, Gachuki BW, Alhakeem SS, Oben KN, Rangnekar V, Gupta RC, Bondada S. Anti-cancer activity of withaferin a in b-cell lymphoma. Cancer Biology & Therapy. 0. PMID 26020511 DOI: 10.1080/15384047.2015.1046651 |
0.46 |
|
| 2015 |
Nooti S, McKenna M, Gachuki B, Byrd J, Muthusamy N, Rangnekar V, Bondada S. Role of Prostate apoptosis response-4 tumor suppressor in the survival and growth of Chronic Lymphocytic Leukemia Clinical Lymphoma Myeloma and Leukemia. 15: S28. DOI: 10.1182/Blood.V126.23.1731.1731 |
0.466 |
|
| 2015 |
Nooti SK, McKenna MK, Frissora FW, Gachuki BW, Alhakeem SS, Greene JT, Muthusamy N, Rangnekar VM, Bondada S. Role of Prostate Apoptosis Response-4 Tumor Suppressor in the Survival and Growth of Chronic Lymphocytic Leukemia Blood. 126: 1731-1731. DOI: 10.1182/blood.v126.23.1731.1731 |
0.364 |
|
| 2015 |
Shrestha-Bhattarai T, Burikhanov R, Hebbar N, Qiu S, Zhao Y, Zambetti GP, Rangnekar VM. Abstract A52: Paracrine apoptotic effect of the tumor suppressor p53 is mediated by secreted Par-4 Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A52 |
0.44 |
|
| 2014 |
Burikhanov R, Sviripa VM, Hebbar N, Zhang W, Layton WJ, Hamza A, Zhan CG, Watt DS, Liu C, Rangnekar VM. Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nature Chemical Biology. 10: 924-6. PMID 25218743 DOI: 10.1038/Nchembio.1631 |
0.544 |
|
| 2014 |
Liu Y, Gilbert MR, Kyprianou N, Rangnekar VM, Horbinski C. The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathologica. 128: 723-32. PMID 25135281 DOI: 10.1007/S00401-014-1334-7 |
0.522 |
|
| 2014 |
Hebbar N, Shrestha-Bhattarai T, Rangnekar VM. Cancer-selective apoptosis by tumor suppressor par-4. Advances in Experimental Medicine and Biology. 818: 155-66. PMID 25001535 DOI: 10.1007/978-1-4471-6458-6_7 |
0.567 |
|
| 2014 |
Chen X, Sahasrabuddhe AA, Szankasi P, Chung F, Basrur V, Rangnekar VM, Pagano M, Lim MS, Elenitoba-Johnson KSJ. Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival Cell Death and Differentiation. 21: 1535-1545. PMID 24992930 DOI: 10.1038/Cdd.2014.92 |
0.568 |
|
| 2014 |
de Thonel A, Hazoumé A, Kochin V, Isoniemi K, Jego G, Fourmaux E, Hammann A, Mjahed H, Filhol O, Micheau O, Rocchi P, Mezger V, Eriksson JE, Rangnekar VM, Garrido C. Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells Cell Death &Amp; Disease. 5. PMID 24457960 DOI: 10.1038/Cddis.2013.532 |
0.502 |
|
| 2014 |
Burikhanov R, Shrestha-Bhattarai T, Hebbar N, Qiu S, Zhao Y, Zambetti GP, Rangnekar VM. Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4. Cell Reports. 6: 271-7. PMID 24412360 DOI: 10.1016/J.Celrep.2013.12.020 |
0.443 |
|
| 2013 |
Hebbar N, Shrestha-Bhattarai T, Rangnekar VM. Par-4 prevents breast cancer recurrence. Breast Cancer Research : Bcr. 15: 314. PMID 24164776 DOI: 10.1186/Bcr3562 |
0.352 |
|
| 2013 |
Shrestha-Bhattarai T, Hebbar N, Rangnekar VM. Par(-4)oxysm in breast cancer. Cancer Cell. 24: 3-5. PMID 23845436 DOI: 10.1016/J.Ccr.2013.06.010 |
0.405 |
|
| 2013 |
Pereira MC, de Bessa-Garcia SA, Burikhanov R, Pavanelli AC, Antunes L, Rangnekar VM, Nagai MA. Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in MCF-7 breast cancer cells. International Journal of Oncology. 43: 531-8. PMID 23760770 DOI: 10.3892/Ijo.2013.1983 |
0.556 |
|
| 2013 |
Burikhanov R, Shrestha-Bhattarai T, Qiu S, Shukla N, Hebbar N, Lele SM, Horbinski C, Rangnekar VM. Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4. Cancer Research. 73: 1011-9. PMID 23204231 DOI: 10.1158/0008-5472.Can-12-3212 |
0.55 |
|
| 2013 |
Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, ... ... Rangnekar V, et al. CELL BIOLOGY AND SIGNALING Neuro-Oncology. 15: iii12-iii31. DOI: 10.1093/Neuonc/Not174 |
0.313 |
|
| 2012 |
Hebbar N, Wang C, Rangnekar VM. Mechanisms of apoptosis by the tumor suppressor Par-4. Journal of Cellular Physiology. 227: 3715-21. PMID 22552839 DOI: 10.1002/Jcp.24098 |
0.49 |
|
| 2012 |
Warren GW, Romano MA, Kudrimoti MR, Randall ME, McGarry RC, Singh AK, Rangnekar VM. Nicotinic modulation of therapeutic response in vitro and in vivo. International Journal of Cancer. Journal International Du Cancer. 131: 2519-27. PMID 22447412 DOI: 10.1002/Ijc.27556 |
0.339 |
|
| 2011 |
Kudrimoti MR, Arnold SM, Valentino J, Gal T, Hyland A, Singh A, Rangnekar V, Cummings KM, Marshall JR, Warren GW. The accuracy of tobacco assessment during definitive radiotherapy or chemoradiotherapy in patients with head and neck cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1556. PMID 28024044 DOI: 10.1200/Jco.2011.29.15_Suppl.1556 |
0.317 |
|
| 2011 |
Zhao Y, Burikhanov R, Brandon J, Qiu S, Shelton BJ, Spear B, Bondada S, Bryson S, Rangnekar VM. Systemic Par-4 inhibits non-autochthonous tumor growth. Cancer Biology & Therapy. 12: 152-7. PMID 21613819 DOI: 10.4161/Cbt.12.2.15734 |
0.509 |
|
| 2010 |
Shrestha-Bhattarai T, Rangnekar VM. Cancer-selective apoptotic effects of extracellular and intracellular Par-4 Oncogene. 29: 3873-3880. PMID 20440265 DOI: 10.1038/Onc.2010.141 |
0.515 |
|
| 2010 |
Schwarze S, Rangnekar VM. Targeting plasma membrane GRP78 for cancer growth inhibition. Cancer Biology & Therapy. 9: 153-5. PMID 20026905 DOI: 10.4161/Cbt.9.2.10760 |
0.51 |
|
| 2010 |
Warren GW, Singh A, Randall M, McGarry R, Kudrimoti M, Rangnekar V. Abstract 3729: Prognostication using Hif-1 alpha may require simultaneous nicotine assessment Cancer Research. 70: 3729-3729. DOI: 10.1158/1538-7445.Am10-3729 |
0.326 |
|
| 2010 |
Warren GW, Randall M, McGarry R, Kudrimoti M, Rangnekar V. Abstract 1408: Nicotine decreases the therapeutic efficacy of radiotherapy and chemoradiotherapy in vivo Cancer Research. 70: 1408-1408. DOI: 10.1158/1538-7445.Am10-1408 |
0.308 |
|
| 2009 |
Warren GW, Kudrimoti M, McGarry R, Arnold S, Rangnekar V. Mechanisms of nicotine-induced resistance to treatment with chemotherapy and radiotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e22008. PMID 27963179 DOI: 10.1200/Jco.2009.27.15_Suppl.E22008 |
0.351 |
|
| 2009 |
Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell. 138: 377-88. PMID 19632185 DOI: 10.1016/J.Cell.2009.05.022 |
0.552 |
|
| 2009 |
Park S, Zhao D, Hatanpaa KJ, Mickey BE, Saha D, Boothman DA, Story MD, Wong ET, Burma S, Georgescu MM, Rangnekar VM, Chauncey SS, Habib AA. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Research. 69: 4107-11. PMID 19435890 DOI: 10.1158/0008-5472.Can-09-0474 |
0.449 |
|
| 2009 |
Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM. The Tumor Suppressor Par-4 Activates an Extrinsic Pathway for Apoptosis (DOI:10.1016/j.cell.2009.05.022) Cell. 138: 1032. DOI: 10.1016/j.cell.2009.08.015 |
0.367 |
|
| 2008 |
Zhao Y, Rangnekar VM. Apoptosis and tumor resistance conferred by Par-4. Cancer Biology & Therapy. 7: 1867-74. PMID 18836307 DOI: 10.4161/Cbt.7.12.6945 |
0.444 |
|
| 2008 |
Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J, Wang S, Sarkar FH, Mohammad RM. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Molecular Cancer Therapeutics. 7: 2884-93. PMID 18790769 DOI: 10.1158/1535-7163.Mct-08-0438 |
0.553 |
|
| 2008 |
Wheeler DL, Rangnekar VM, Schwarze SR. ErbB4 targeting approaches for prostate cancer treatment. Cancer Biology & Therapy. 7: 1095-7. PMID 18698169 DOI: 10.4161/Cbt.7.7.6537 |
0.387 |
|
| 2008 |
Goswami A, Qiu S, Dexheimer TS, Ranganathan P, Burikhanov R, Pommier Y, Rangnekar VM. Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity. Cancer Research. 68: 6190-8. PMID 18676842 DOI: 10.1158/0008-5472.Can-08-0831 |
0.37 |
|
| 2008 |
Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharmaceutical Research. 25: 2117-24. PMID 18427961 DOI: 10.1007/S11095-008-9581-8 |
0.508 |
|
| 2008 |
Warren G, Rangnekar V, McGarry R, Arnold S, Valentino J, Kudrimoti M. Pathways of Resistance: Potential Effects of Nicotine on Cancer and Treatment Response International Journal of Radiation Oncology*Biology*Physics. 72: S715. DOI: 10.1016/J.Ijrobp.2008.06.552 |
0.343 |
|
| 2007 |
Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, Shajahan S, Mohiuddin M, Rangnekar VM, Ahmed MM. Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Research. 67: 11811-20. PMID 18089811 DOI: 10.1158/0008-5472.Can-07-0722 |
0.385 |
|
| 2007 |
Vasudevan KM, Burikhanov R, Goswami A, Rangnekar VM. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Research. 67: 10343-50. PMID 17974977 DOI: 10.1158/0008-5472.Can-07-1827 |
0.792 |
|
| 2007 |
Zhao Y, Burikhanov R, Qiu S, Lele SM, Jennings CD, Bondada S, Spear B, Rangnekar VM. Cancer resistance in transgenic mice expressing the SAC module of Par-4 Cancer Research. 67: 9276-9285. PMID 17909035 DOI: 10.1158/0008-5472.Can-07-2124 |
0.506 |
|
| 2007 |
Sun Y, St Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA, St Clair WH. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Molecular Cancer Therapeutics. 6: 2477-86. PMID 17876045 DOI: 10.1158/1535-7163.Mct-07-0186 |
0.562 |
|
| 2007 |
Gupta V, Yeo G, Kawakubo H, Rangnekar V, Ramaswamy P, Hayashida T, MacLaughlin DT, Donahoe PK, Maheswaran S. Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism. Cancer Research. 67: 2747-56. PMID 17363596 DOI: 10.1158/0008-5472.Can-06-2312 |
0.367 |
|
| 2007 |
Languino LR, Rangnekar VM. "D" approach to prevent metastasis. Cancer Biology & Therapy. 6: 110-1. PMID 17264669 DOI: 10.4161/Cbt.6.1.3786 |
0.339 |
|
| 2007 |
Gururajan M, Dasu T, Shahidain S, Jennings CD, Robertson DA, Rangnekar VM, Bondada S. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth Journal of Immunology. 178: 111-121. PMID 17182546 DOI: 10.4049/Jimmunol.178.1.111 |
0.387 |
|
| 2007 |
St. Clair W, Sun Y, St. Clair D, Fang F, Warren G, Rangnekar V, Crooks P. The NF-κB–PTEN Axis Enhances Radiation Sensitivity of Prostate Cancer Cells International Journal of Radiation Oncology*Biology*Physics. 69: S611. DOI: 10.1016/J.Ijrobp.2007.07.1924 |
0.45 |
|
| 2006 |
Vasudevan KM, Ranganathan P, Rangnekar VM. Regulation of Par-4 by oncogenic Ras. Methods in Enzymology. 407: 422-42. PMID 16757343 DOI: 10.1016/S0076-6879(05)07035-7 |
0.787 |
|
| 2006 |
Goswami A, Ranganathan P, Rangnekar VM. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Research. 66: 2889-92. PMID 16540633 DOI: 10.1158/0008-5472.Can-05-4458 |
0.486 |
|
| 2005 |
Ranganathan P, Rangnekar VM. Regulation of cancer cell survival by Par-4. Annals of the New York Academy of Sciences. 1059: 76-85. PMID 16382046 DOI: 10.1196/Annals.1339.046 |
0.573 |
|
| 2005 |
Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y, Eriksson JE, Tsuruo T, Rangnekar VM. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Molecular Cell. 20: 33-44. PMID 16209943 DOI: 10.1016/J.Molcel.2005.08.016 |
0.566 |
|
| 2005 |
Ranganathan P, Rangnekar VM. Exploiting the TSA connections to overcome apoptosis-resistance. Cancer Biology & Therapy. 4: 391-2. PMID 15908800 DOI: 10.4161/Cbt.4.4.1779 |
0.432 |
|
| 2005 |
Pruitt K, Ulkü AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, Der CJ, Shields JM. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. The Journal of Biological Chemistry. 280: 23363-70. PMID 15831492 DOI: 10.1074/Jbc.M503083200 |
0.397 |
|
| 2005 |
Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Molecular and Cellular Biology. 25: 1146-61. PMID 15657440 DOI: 10.1128/Mcb.25.3.1146-1161.2005 |
0.8 |
|
| 2004 |
Rege YD, Rangnekar VM. Molecular therapy intervention prospects in prostate cancer. Current Pharmaceutical Design. 10: 523-30. PMID 14965337 DOI: 10.2174/1381612043453234 |
0.381 |
|
| 2004 |
Gurumurthy S, Rangnekar VM. Par-4 inducible apoptosis in prostate cancer cells. Journal of Cellular Biochemistry. 91: 504-12. PMID 14755681 DOI: 10.1002/Jcb.20000 |
0.544 |
|
| 2004 |
Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Molecular and Cellular Biology. 24: 1007-21. PMID 14729949 DOI: 10.1128/Mcb.24.3.1007-1021.2004 |
0.769 |
|
| 2003 |
El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Molecular and Cellular Biology. 23: 5516-25. PMID 12897127 DOI: 10.1128/Mcb.23.16.5516-5525.2003 |
0.812 |
|
| 2003 |
Yang CC, Lin HP, Chen CS, Yang YT, Tseng PH, Rangnekar VM, Chen CS. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. The Journal of Biological Chemistry. 278: 25872-8. PMID 12738789 DOI: 10.1074/Jbc.M301744200 |
0.58 |
|
| 2003 |
Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. The Journal of Biological Chemistry. 278: 19995-20005. PMID 12644474 DOI: 10.1074/Jbc.M205865200 |
0.535 |
|
| 2003 |
Butler J, Rangnekar VM. Par-4 for molecular therapy of prostate cancer. Current Drug Targets. 4: 223-30. PMID 12643472 |
0.343 |
|
| 2003 |
El-Guendy N, Rangnekar VM. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Experimental Cell Research. 283: 51-66. PMID 12565819 DOI: 10.1016/S0014-4827(02)00016-2 |
0.826 |
|
| 2002 |
Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Research. 62: 1768-75. PMID 11912153 |
0.419 |
|
| 2001 |
Gurumurthy S, Vasudevan KM, Rangnekar VM. Regulation of apoptosis in prostate cancer. Cancer Metastasis Reviews. 20: 225-43. PMID 12085964 DOI: 10.1023/A:1015583310759 |
0.796 |
|
| 2001 |
Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Research. 61: 7255-63. PMID 11585763 |
0.814 |
|
| 2001 |
Porntadavity S, Xu Y, Kiningham K, Rangnekar VM, Prachayasitikul V, St. Clair DK. TPA-activated transcription of the human MnSOD gene: Role of transcription factors SP-1 and Egr-1 Dna and Cell Biology. 20: 473-481. PMID 11560779 DOI: 10.1089/104454901316976109 |
0.315 |
|
| 2001 |
Lucas T, Pratscher B, Krishnan S, Fink D, Günsberg P, Wolschek M, Wacheck V, Muster T, Romirer I, Wolff K, Pehamberger H, Eichler HG, Rangnekar VM, Jansen B. Differential expression levels of Par-4 in melanoma Melanoma Research. 11: 379-383. PMID 11479426 DOI: 10.1097/00008390-200108000-00008 |
0.362 |
|
| 2001 |
Boehrer S, Chow KU, Puccetti E, Ruthardt M, Godzisard S, Krapohl A, Schneider B, Hoelzer D, Mitrou PS, Rangnekar VM, Weidmann E. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia Hematology Journal. 2: 103-107. PMID 11424002 DOI: 10.1038/Sj/Thj/6200089 |
0.465 |
|
| 2001 |
Das A, Chendil D, Dey S, Mohiuddin M, Milbrandt J, Rangnekar VM, Ahmed MM. Ionizing Radiation Down-regulates p53 Protein in Primary Egr-1 -/- Mouse Embryonic Fibroblast Cells Causing Enhanced Resistance to Apoptosis Journal of Biological Chemistry. 276: 3279-3286. PMID 11035041 DOI: 10.1074/Jbc.M008454200 |
0.402 |
|
| 2001 |
Rangnekar VM. Apoptosis by par-4 protein Advances in Cell Aging and Gerontology. 5: 215-236. |
0.468 |
|
| 2000 |
Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. The Journal of Biological Chemistry. 275: 11397-403. PMID 10753955 DOI: 10.1074/Jbc.275.15.11397 |
0.558 |
|
| 2000 |
Page G, Kögel D, Rangnekar V, Scheidtmann KH. Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis. Oncogene. 18: 7265-73. PMID 10602480 DOI: 10.1038/Sj.Onc.1203170 |
0.342 |
|
| 1999 |
Qiu SG, Krishnan S, El-Guendy N, Rangnekar VM. Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation Oncogene. 18: 7115-7123. PMID 10597313 DOI: 10.1038/Sj.Onc.1203199 |
0.784 |
|
| 1999 |
Nalca A, Qiu SG, El-Guendy N, Krishnan S, Rangnekar VM. Oncogenic Ras sensitizes cells to apoptosis by Par-4 Journal of Biological Chemistry. 274: 29976-29983. PMID 10514481 DOI: 10.1074/Jbc.274.42.29976 |
0.803 |
|
| 1999 |
Duan W, Rangnekar VM, Mattson MP. Prostate apoptosis response-4 production in synaptic compartments following apoptotic and excitotoxic insults: Evidence for a pivotal role in mitochondrial dysfunction and neuronal degeneration Journal of Neurochemistry. 72: 2312-2322. PMID 10349840 DOI: 10.1046/J.1471-4159.1999.0722312.X |
0.383 |
|
| 1999 |
Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH, Rangnekar VM. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene. 18: 1205-8. PMID 10022126 DOI: 10.1038/Sj.Onc.1202416 |
0.421 |
|
| 1999 |
Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH, Rangnekar VM. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene. 18: 623-31. PMID 9989812 DOI: 10.1038/Sj.Onc.1202344 |
0.499 |
|
| 1998 |
Guo Q, Fu W, Xie J, Luo H, Sells SF, Geddes JW, Bondada V, Rangnekar VM, Mattson MP. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nature Medicine. 4: 957-62. PMID 9701251 DOI: 10.1038/Nm0898-957 |
0.441 |
|
| 1998 |
Rangnekar VM. Apoptosis mediated by a novel leucine zipper protein Par-4 Apoptosis. 3: 61-66. |
0.484 |
|
| 1997 |
Ahmed MM, Sells SF, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Harp C, Mohiuddin M, Rangnekar VM. Ionizing radiation-inducible apoptosis in the absence of p53 linked to transcription factor EGR-1. The Journal of Biological Chemistry. 272: 33056-61. PMID 9407088 DOI: 10.1074/Jbc.272.52.33056 |
0.458 |
|
| 1997 |
Muthukkumar S, Han SS, Rangnekar VM, Bondada S. Role of Egr-1 gene expression in B cell receptor-induced apoptosis in an immature B cell lymphoma Journal of Biological Chemistry. 272: 27987-27993. PMID 9346950 DOI: 10.1074/Jbc.272.44.27987 |
0.423 |
|
| 1997 |
Boghaert ER, Sells SF, Walid AJ, Malone P, Williams NM, Weinstein MH, Strange R, Rangnekar VM. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 8: 881-90. PMID 9269897 |
0.374 |
|
| 1997 |
Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM. Early growth response-1-dependent apoptosis is mediated by p53. The Journal of Biological Chemistry. 272: 20131-8. PMID 9242687 DOI: 10.1074/jbc.272.32.20131 |
0.333 |
|
| 1997 |
Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, Gillis D, Liu G, Nair P, Monnig S, Collini P, Mattson MP, Sukhatme VP, Zimmer SG, Wood DP, ... ... Rangnekar VM, et al. Expression and function of the leucine zipper protein Par-4 in apoptosis. Molecular and Cellular Biology. 17: 3823-32. PMID 9199316 DOI: 10.1128/Mcb.17.7.3823 |
0.558 |
|
| 1996 |
Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Molecular and Cellular Biology. 16: 6945-56. PMID 8943350 DOI: 10.1128/Mcb.16.12.6945 |
0.305 |
|
| 1996 |
Ahmed MM, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Wood DP, Sells SF, Mohiuddin M, Rangnekar VM. EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. The Journal of Biological Chemistry. 271: 29231-7. PMID 8910582 DOI: 10.1074/Jbc.271.46.29231 |
0.363 |
|
| 1996 |
Muthukkumar S, Sells SF, Crist SA, Rangnekar VM. Interleukin-1 induces growth arrest by hypophosphorylation of the retinoblastoma susceptibility gene product RB. The Journal of Biological Chemistry. 271: 5733-40. PMID 8621439 DOI: 10.1074/Jbc.271.10.5733 |
0.303 |
|
| 1995 |
Sells SF, Muthukumar S, Sukhatme VP, Crist SA, Rangnekar VM. The zinc finger transcription factor EGR-1 impedes interleukin-1-inducible tumor growth arrest. Molecular and Cellular Biology. 15: 682-92. PMID 7823937 DOI: 10.1128/Mcb.15.2.682 |
0.353 |
|
| 1995 |
Muthukkumar S, Nair P, Sells SF, Maddiwar NG, Jacob RJ, Rangnekar VM. Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6. Molecular and Cellular Biology. 15: 6262-72. PMID 7565779 DOI: 10.1128/Mcb.15.11.6262 |
0.471 |
|
| 1994 |
Sells SF, Wood DP, Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S, Rangnekar VM. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 5: 457-66. PMID 8043520 |
0.392 |
|
| 1994 |
Wood DP, Banks ER, Humphreys S, Rangnekar VM. Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 42: 505-11. PMID 7510319 DOI: 10.1177/42.4.7510319 |
0.434 |
|
| Show low-probability matches. |